Carbidopa
From Wikipedia, the free encyclopedia
| Image:Carbidopa.svg | |
| Carbidopa
| |
| Systematic (IUPAC) name | |
| (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl- propanoic acid | |
| Identifiers | |
| CAS number | 28860-95-9 |
| ATC code | ? |
| PubChem | 34359 |
| DrugBank | APRD00160 |
| Chemical data | |
| Formula | C10H14N2O4 |
| Mol. weight | 226.229 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 76% |
| Metabolism | decarboxylated to dopamine in extracerebral tissues |
| Half life | 1-2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
? |
| Legal status |
POM(UK) |
| Routes | ? |
Carbidopa (MK-486) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa.
Carbidopa inhibits aromatic-L-amino-acid decarboxylase (DOPA Decarboxylase or DDC), an enzyme important in the biosynthesis of L-tryptophan to serotonin and in the biosynthesis of L-DOPA to Dopamine (DA). Along with carbidopa, other DDC inhibitors are benserazide (Ro-4-4602), difluromethyldopa, and a-methyldopa.
Used in tandem with L-DOPA (trade name levodopa, a dopamine precursor converted in the body to dopamine), it increases the plasma half-life of levodopa from 50 minutes to 1 1/2 hours. CarbiDOPA cannot cross the blood brain barrier, so it inhibits only peripheral DDC. It thus prevents the conversion of L-DOPA to dopamine peripherally. This reduces the side effects caused by dopamine on the periphery, as well as increasing the concentration of L-DOPA and dopamine in the brain.
The combination of L-DOPA and carbiDOPA carries the brand names of Sinemet®, Parcopa® and Atamet®.
[edit] External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
